Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?

Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?

wallstreetcn02:50 ET

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Benzinga17:00 ET

Friday Market Rebounds Some of Weeks Loss | Wall Street Today

Kevin Travers16:06 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga16:06 ET

What's Going On With Amgen Stock On Friday?

Benzinga14:40 ET

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

Benzinga13:05 ET